Know Cancer

or
forgot password

Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma


N/A
19 Years
N/A
Open (Enrolling)
Both
Hepatocellular Carcinoma, Transarterial Chemoembolization

Thank you

Trial Information

Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma


Subjective angiographic chemoembolization endpoints (SACE) levels were developed to
standardize the embolic endpoints of transarterial chemoembolization (TACE) for
hepatocellular carcinoma (HCC). It determined the antegrade arterial flow and residual tumor
blush as follows: I, normal-normal; II, reduced-reduced; III, reduced-none; IV, none-none.
SACE level II and III indicates intermediate-levels of embolization, whereas IV indicates
overembolization. The aim of this study was to evaluate whether survival of patients who
underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.


Inclusion Criteria:



- age over 18

- ECOG performance status 0-2

- Hepatocellular carcinoma diagnosed histologically or clinically

- Tumor numbers of 5 or less

- No history of treatment for hepatocellular carcinoma

- Patients with informed consent

Exclusion Criteria:

- Extrahepatic metastasis

- Rupture of hepatocellular carcinoma

- Infiltrative hepatocellular carcinoma

- Malignancy other than hepatocellular carcinoma

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Outcome Measure:

Survival rate of the subjects

Outcome Description:

Survival rate of the subjects 6 months after TACE

Outcome Time Frame:

6 months after TACE

Safety Issue:

No

Principal Investigator

Sang Hoon Park, M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hallym University Medical Center

Authority:

South Korea: Institutional Review Board

Study ID:

2011-12-122

NCT ID:

NCT01677468

Start Date:

August 2012

Completion Date:

July 2015

Related Keywords:

  • Hepatocellular Carcinoma
  • Transarterial Chemoembolization
  • Hepatocellular carcinoma
  • Transarterial chemoembolization
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location